---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026739"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T03:01:21.331388+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma elects James Flynn to Board; annual meeting results

## Summary
- James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.
- Flynn granted option to purchase 12,000 shares at $2.32; other directors each granted 6,000-share options.
- Stockholders elected Grais, Hove, Flynn; ratified KPMG as auditor; approved executive compensation.
- Board is evaluating strategic options for the company, per press release.

## SEC filing metadata
- accession: 0000950170-22-026739
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/abio-20221215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026739
- JSON: https://secwatch.observer/filing/0000950170-22-026739.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026739.txt

## Key facts
- Executive change
  James Flynn was elected as director at Oruka Therapeutics, Inc..
  - Action: elected
  - Role: director
  source text: On December 15, 2022, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) elected James Flynn, as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2022-12-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2022-12-15
  source text: 1. Election of Directors: Nominee For Withheld Broker Non-Votes Dr. Linda Grais 5,625,386 192,401 3,296,871 Dr. Anders Hove 5,331,324 486,463 3,296,871 Mr. James Flynn 5,616,593 201,194 3,296,871
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-12-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2022-12-15
  source text: 2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Abstentions Broker Non-Votes 8,980,366 116,906 17,386 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2022-12-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2022-12-15
  source text: 3. Executive Compensation: For Against Abstentions Broker Non-Votes 5,301,245 456,787 59,755 3,296,871
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.